Literature DB >> 26829368

Characterization and Higher-Order Structure Assessment of an Interchain Cysteine-Based ADC: Impact of Drug Loading and Distribution on the Mechanism of Aggregation.

Jianxin Guo, Sandeep Kumar, Mark Chipley, Olivier Marcq, Devansh Gupta1, Zhaowei Jin, Dheeraj S Tomar, Cecily Swabowski, Jacquelynn Smith, Jason A Starkey, Satish K Singh.   

Abstract

The impact of drug loading and distribution on higher order structure and physical stability of an interchain cysteine-based antibody drug conjugate (ADC) has been studied. An IgG1 mAb was conjugated with a cytotoxic auristatin payload following the reduction of interchain disulfides. The 2-D LC-MS analysis shows that there is a preference for certain isomers within the various drug to antibody ratios (DARs). The physical stability of the unconjugated monoclonal antibody, the ADC, and isolated conjugated species with specific DAR, were compared using calorimetric, thermal, chemical denaturation and molecular modeling techniques, as well as techniques to assess hydrophobicity. The DAR was determined to have a significant impact on the biophysical properties and stability of the ADC. The CH2 domain was significantly perturbed in the DAR6 species, which was attributable to quaternary structural changes as assessed by molecular modeling. At accelerated storage temperatures, the DAR6 rapidly forms higher molecular mass species, whereas the DAR2 and the unconjugated mAb were largely stable. Chemical denaturation study indicates that DAR6 may form multimers while DAR2 and DAR4 primarily exist in monomeric forms in solution at ambient conditions. The physical state differences were correlated with a dramatic increase in the hydrophobicity and a reduction in the surface tension of the DAR6 compared to lower DAR species. Molecular modeling of the various DAR species and their conformers demonstrates that the auristatin-based linker payload directly contributes to the hydrophobicity of the ADC molecule. Higher order structural characterization provides insight into the impact of conjugation on the conformational and colloidal factors that determine the physical stability of cysteine-based ADCs, with implications for process and formulation development.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26829368     DOI: 10.1021/acs.bioconjchem.5b00603

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  10 in total

1.  Evidence of disulfide bond scrambling during production of an antibody-drug conjugate.

Authors:  Lily Pei-Yao Liu-Shin; Adam Fung; Arun Malhotra; Gayathri Ratnaswamy
Journal:  MAbs       Date:  2018-10-19       Impact factor: 5.857

Review 2.  Challenges and new frontiers in analytical characterization of antibody-drug conjugates.

Authors:  Anil Wagh; Hangtian Song; Ming Zeng; Li Tao; Tapan K Das
Journal:  MAbs       Date:  2018-01-05       Impact factor: 5.857

Review 3.  Effects of localized interactions and surface properties on stability of protein-based therapeutics.

Authors:  Brittney J Mills; Jennifer S Laurence Chadwick
Journal:  J Pharm Pharmacol       Date:  2016-11-10       Impact factor: 3.765

4.  The Properties of Cysteine-Conjugated Antibody-Drug Conjugates Are Impacted by the IgG Subclass.

Authors:  Amita Datta-Mannan; Hiuwan Choi; David Stokell; Jason Tang; Anthony Murphy; Aaron Wrobleski; Yiqing Feng
Journal:  AAPS J       Date:  2018-09-25       Impact factor: 4.009

5.  Influence of disulfide bond isoforms on drug conjugation sites in cysteine-linked IgG2 antibody-drug conjugates.

Authors:  Lily Liu-Shin; Adam Fung; Arun Malhotra; Gayathri Ratnaswamy
Journal:  MAbs       Date:  2018-03-06       Impact factor: 5.857

6.  High-Throughput, Multispecies, Parallelized Plasma Stability Assay for the Determination and Characterization of Antibody-Drug Conjugate Aggregation and Drug Release.

Authors:  Kenneth R Durbin; M Shannon Nottoli; Nathaniel D Catron; Nicole Richwine; Gary J Jenkins
Journal:  ACS Omega       Date:  2017-08-03

7.  Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing.

Authors:  Dina Lakayan; Rob Haselberg; Rabah Gahoual; Govert W Somsen; Jeroen Kool
Journal:  Anal Bioanal Chem       Date:  2018-10-17       Impact factor: 4.142

Review 8.  Antibody Conjugates-Recent Advances and Future Innovations.

Authors:  Donmienne Leung; Jacqueline M Wurst; Tao Liu; Ruben M Martinez; Amita Datta-Mannan; Yiqing Feng
Journal:  Antibodies (Basel)       Date:  2020-01-08

Review 9.  Antibody drug conjugate: the "biological missile" for targeted cancer therapy.

Authors:  Zhiwen Fu; Shijun Li; Sifei Han; Chen Shi; Yu Zhang
Journal:  Signal Transduct Target Ther       Date:  2022-03-22

10.  A poly-ADP-ribose polymer-based antibody-drug conjugate.

Authors:  Xiaojing Shi; Xiao-Nan Zhang; Jingwen Chen; Qinqin Cheng; Hua Pei; Stan G Louie; Yong Zhang
Journal:  Chem Sci       Date:  2020-08-17       Impact factor: 9.825

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.